therapeutic and diagnostic products that include two or more regulated components. Understanding how the user interacts with each component is vital. A comprehensive human factors analysis helps inform the design process, and ultimately, the regulatory submission strategy. Begin by reviewing guidance documents, such as the FDA’s Guidance on Human Factors and Usability Engineering for Medical Devices, as well as the relevant sections from the Office of Combination Products (OCP).

Step 2: Developing a Human Factors Plan

A Human Factors Plan (HFP) serves as a roadmap for integrating HFE into the design and evaluation of combination products. Here are essential components to include:

• Objectives: Clearly outline the goals for your HFE activities. This could include identifying specific user groups and key tasks associated with the product’s use.
• Stakeholder Engagement: Involve users early in the development process to understand their needs and expectations. This could be achieved through focus groups or surveys.
• Methodologies: Specify which methodologies you will use for evaluating the product from a human factors perspective, such as formative and summative testing.
• Timeline: Establish the timeline for executing human factors activities and integrate it into the overall project management timeline.
• Documentation: Set clear expectations for documenting HFE activities, including details about evaluations, findings, and design iterations.

It is crucial to tailor your HFP to reflect your specific combination product’s context, user population, and intended use. The FDA encourages continuous refinement based on user feedback to ensure that the final design meets usability requirements.

Step 3: Conducting Formative Research

Formative research involves iterative testing and evaluation conducted during the design and development stages. The purpose of this research is to uncover potential usability issues that could lead to user errors. Key activities include:

• User Observations: Conduct observations of end-users in a controlled environment to identify behaviors that may lead to errors.
• Usability Testing: Perform task-based usability tests to collect qualitative and quantitative data. This can involve creating prototypes or simulations of your combination product.
• Iterative Design: Based on feedback from observations and usability testing, iteratively improve the design of the product. For instance, if users struggle with a certain feature, consider redesigning it for clarity.
• Compile Findings: Document all observations, user feedback, and changes made to the product. This documented evidence will be crucial for your regulatory submission.

Effective formative research will not only help to create a safer and more user-friendly product but also demonstrates to the FDA your commitment to addressing human factors. For guidance on designing human factors studies, refer to the FDA’s Human Factors Guidance.

Step 4: Implementing Summative Testing

Summative testing is the final evaluation of the product, aimed at verifying that it meets user needs and safety requirements before market introduction. This phase is critical as it provides the evidence needed for FDA review. Key steps include:

• Preparing Study Protocols: Develop detailed protocols for summative testing that outline objectives, methodologies, participant criteria, and statistical analyses.
• Selecting Participants: Ensure that the testing population closely mirrors the intended user groups for your combination product.
• Executing Usability Studies: Conduct formal usability studies under conditions that simulate actual usage. This includes evaluating error rates and the ability to complete critical tasks.
• Data Analysis: Analyze the results to assess whether the product meets predefined usability criteria and objectives.
• Final Documentation: Document the methodology, findings, and any changes made in response to testing outcomes. This should be readily available for inclusion in your regulatory submission.

Summative testing adds a layer of validation to your human factors efforts, ultimately providing the FDA with confidence that your combination product can be used safely and effectively by its intended users.

Step 5: Preparing Your Regulatory Submission

Once human factors documentation is completed, the next step is integrating this information into your regulatory submission. Depending on the pathway you choose (e.g. 510(k), PMA, NDA, or BLA), there are specific requirements for including human factors data:

• 510(k) Submissions: For devices needing 510(k) clearance, include a human factors summary and Describe how the product meets FDA criteria for substantial equivalence.
• PMA Submissions: In cases of a Premarket Approval Application (PMA), provide a robust human factors section that addresses usability issues and summarizes results from formative and summative testing.
• NDA/BLA Submissions: New Drug Applications (NDA) and Biologics License Applications (BLA) should include human factors assessments that demonstrate the design and usability of drug delivery systems.
• Common Requirements: Regardless of the pathway, ensure you comply with general usability reporting requirements as outlined by the FDA.

Given the complexity of some combination products, it may be beneficial to engage in FDA combination product consulting for regulatory strategy and submission assistance. Consider leveraging external expertise to ensure your submission meets all expectations.

Step 6: Navigating Post-Approval Commitments

After gaining FDA approval for your combination product, your regulatory responsibilities do not end. It is essential to have a plan for post-approval commitments related to human factors:

• Post-Market Surveillance: Implement a system for gathering real-world user feedback. Monitor user experiences to identify any new usability issues that may arise once the product is on the market.
• Risk Management: Continually assess risks associated with new or evolving user interactions with your product. Update your risk management files and address any emerging issues.
• User Education and Training: Provide adequate training materials and resources to users to enhance device usability and ensure safe use.
• Product Updates: If significant usability concerns are identified through post-market surveillance, be prepared to undertake product revisions and submit the necessary reports to the FDA.

Fulfilling post-approval commitments ensures that you maintain compliance and continuously optimize your product’s usability throughout its lifecycle.

Conclusion

Addressing human factors in FDA combination product reviews is a multifaceted process that demands attention to detail and systematic planning. By following each of the steps outlined in this guide—from understanding human factors to managing post-approval commitments—you will significantly enhance the likelihood of a successful regulatory submission. For more information, consult the relevant FDA guidance documents available on the FDA website. Engaging experienced professionals in FDA combination product consulting can also streamline your efforts and optimize your approach. With thorough preparation, your combination product can provide the intended therapeutic benefits safely and efficiently.